Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Primordial Genetics announced an exclusive license agreement with Arcturus Therapeutics Holdings Inc. (ARCT) for a novel RNA polymerase enzyme, aimed at enhancing the manufacturing of long, high-quality RNAs for therapeutic use. This collaboration is expected to significantly improve the efficiency and cost-effectiveness of mRNA production, which is vital for drug and vaccine development. Primordial's technology emphasizes innovative RNA manufacturing processes that could lead to advancements in pharmaceuticals, ultimately aiming to address pressing health needs.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q1 2021 financial results, noting revenue of $2.1 million, down from $2.6 million year-over-year. The company incurred a net loss of $56.3 million, reflecting an increase in operating expenses to $59.8 million, driven by higher R&D costs for its ARCT-021 COVID-19 vaccine candidate. The Phase 2 trial for ARCT-021 has completed enrollment with promising interim immunogenicity data supporting plans for a Phase 3 study. Cash reserves are strong at $466.9 million, expected to cover operations for over two years.
Arcturus Therapeutics Holdings (Nasdaq: ARCT) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company focuses on mRNA medicines targeting infectious diseases and rare liver and respiratory diseases. Arcturus has a diverse pipeline including vaccines for SARS-CoV-2 and influenza, as well as programs for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor and scientific conferences. Highlights include:
- Guggenheim Healthcare Talks: April 1, 2021, at 4:00 p.m. ET (Panel Discussion)
- 7th Annual Truist Securities Life Sciences Summit: May 4, 2021, at 1:50 p.m. ET (Fireside Chat)
- Genetic Vaccine Development Summit: May 20, 2021, at 1:30 p.m. ET (Presentation)
Details and presentation links are available on their website.
Arcturus Therapeutics Holdings Inc. (ARCT) reported its 2020 financial results, showing total revenues of $9.5 million, a significant decline from $20.8 million in 2019. The company incurred a net loss of $72.1 million for the year, compared to $26.0 million in the previous year. Despite this, Arcturus is advancing its ARCT-021 COVID-19 vaccine into Phase 3 trials and has received $46.6 million to support its vaccine stockpiling. The company expects its cash position of $463 million to sustain operations for over two years.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the acquisition of an exclusive license from Alexion Pharmaceuticals for patent-pending nucleic acid purification technologies. This strategic move aims to enhance the production efficiency of mRNA, critical for the development of vaccines and therapies. With this technology, Arcturus can scale up mRNA production while ensuring higher purity. This acquisition strengthens Arcturus' existing intellectual property portfolio, which is vital for its operations in RNA medicines and vaccines, including COVID-19 and Influenza.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and year ended December 31, 2020, after market close on March 1, 2021. Following this announcement, a conference call and webcast will take place at 4:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases, with products targeting COVID-19, Influenza, and rare liver and respiratory diseases. The company utilizes its proprietary LUNAR® and STARR™ technologies and is supported by a strong patent portfolio and various collaborations.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor conferences. Notable events include:
- BIO CEO & Investor Digital Conference: February 12, 2021, at 12:00 p.m. ET
- Raymond James Annual Institutional Investors Conference: March 3, 2021, at 11:40 a.m. ET
- H.C. Wainwright Global Life Sciences Conference: March 9, 2021, at 7:00 a.m. ET
- Barclays Global Healthcare Conference: March 10, 2021, at 1:50 p.m. ET
Arcturus focuses on developing vaccines and treatments for infectious diseases.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will engage in a panel discussion at the 13th Annual Biotech Showcase™ Investor Conference.
The discussion, titled COVID-19 Vaccines: All things impacted by COVID-19, will occur on January 11, 2020, at 1:00 p.m. ET. The event can be accessed on-demand from January 12 to March 31, 2020, via the event platform.
Arcturus specializes in mRNA medicines, with a diverse pipeline addressing COVID-19, Influenza, and rare diseases.
Arcturus Therapeutics has received FDA allowance for its IND application regarding the Phase 2 clinical study of its vaccine candidate ARCT-021, based on preceding favorable data from the Phase 1/2 study. The Phase 2 trial will involve 600 participants, evaluating both safety and immunogenicity. The aim is to inform dosing for a prospective Phase 3 study planned for Q2 2021, pending successful results. The ARCT-021 vaccine shows promise for a differentiated profile and may potentially require only a single dose for adequate protection against SARS-CoV-2.